Nasdaq

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) ...
Yahoo Finance

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Submission based on three phase 2 trials where Daiichi Sankyo and AstraZeneca’s ENHERTU showed clinically meaningful responses across a broad range of tumors If approved, ENHERTU would become the ...
Business Wire

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II Variation Application ...
Nasdaq

Vertex Announces EMA Type II Variation Marketing Authorization Application Validation For KAFTRIO

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the European Medicines Agency or EMA has validated a Type II Variation Marketing Authorization ...
Semiconductor Engineering

Model Variation And Its Impact On Cell Characterization

EDA (Electronic Design Automation) cell characterization tools have been used extensively to generate models for timing, power and noise at a rapidly growing number of process corners. Today, model ...
JSTOR Daily

Spatial Variation in Sinusoidal Wave Energy on a Crescentic Nearshore Bar; Application to the Cap-Ferret Coast, France

Simple sinusoidal wave refraction on a crescentic bar off the Aquitaine coast has been studied. In the case of parallel waves to the coast, this bar, composed of a cyclical repetition of troughs ...
Business Wire

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II ...
AFP

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) for the treatment of adult patients with HER2 ...